Duloxetine Capsule, Delayed Release
Product Images NDC 71335-2567

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 71335-2567). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 01)

Chemical structure of Duloxetine hydrochloride showing a naphthalene group connected to a thiophene ring through an oxygen atom, with an attached side chain containing an amine (NH) methylated and associated with hydrochloride (HCl).*

FDA Label Image

Figure 1 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 02)

A Kaplan-Meier curve graph comparing the proportion of patients with relapse over time between Placebo and Duloxetine treatment groups. The x-axis represents time from randomization to relapse in days, and the y-axis shows the proportion of patients with relapse, ranging from 0.0 to 1.0. Placebo data is shown with a dashed line, and Duloxetine data with a solid line, indicating lower relapse proportion over time for Duloxetine.*

FDA Label Image

Figure 2 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 03)

A Kaplan-Meier curve graph showing the proportion of patients with relapse over time in days from randomization. The graph compares two treatment groups: Duloxetine and placebo, with Duloxetine showing a lower proportion of relapse than placebo over approximately 250 days.*

FDA Label Image

Figure 1 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 04)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline. The graph compares Duloxetine 60 mg twice daily (BID), Duloxetine 60 mg once daily (QD), Duloxetine 20 mg once daily (QD), and placebo. The x-axis represents percent improvement in pain from baseline, ranging from 0 to 100%. The y-axis represents the percentage of patients improved, ranging from 0 to 80%. Lines for the different treatment groups show patient improvement trends across pain improvement percentages.*

FDA Label Image

Figure 2 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 05)

A line graph depicting the percentage of patients improved plotted against percent improvement in pain from baseline. It compares three groups: Duloxetine 60 mg twice daily (BID), Duloxetine 60 mg once daily (QD), and placebo. The graph shows that patients taking Duloxetine experience a higher percentage of pain improvement compared to placebo at various thresholds of improvement.*

FDA Label Image

Fig 5 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 06)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline. It shows three groups: Duloxetine 60 mg twice daily, Duloxetine 60 mg once daily, and placebo. The vertical axis represents the percentage of patients improved from 0 to 100%, and the horizontal axis shows percent improvement in pain, with reference lines at 30% and 50% improvements.*

FDA Label Image

Fig 6 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 07)

A line graph comparing the percentage of patients improved against the percent improvement in pain from baseline for Duloxetine 120 mg twice daily, Duloxetine 60 mg once daily (two different data series), and placebo. The x-axis shows percent improvement in pain, while the y-axis shows percentage of patients improved, with the Duloxetine treatments generally showing higher patient improvement percentages compared to placebo.*

FDA Label Image

Fig 7 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 08)

A line graph displaying the percentage of pediatric patients aged 13 to 17 with juvenile fibromyalgia syndrome achieving various levels of pain relief at week 12. The graph compares Duloxetine 60 mg once daily to placebo, showing percentage improvement in pain from baseline on the x-axis and percentage of patients improved on the y-axis.*

FDA Label Image

Figure 8 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 09)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF) for Duloxetine 60/120 mg once daily and placebo. The x-axis shows percent improvement in pain, ranging from >0 to 100%, and the y-axis shows the percentage of patients improved, ranging from 0 to 100%. Two lines represent duloxetine and placebo groups, with duloxetine consistently showing higher patient improvement percentages.*

FDA Label Image

Figure 9 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 10)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF) for Duloxetine 60 mg once daily and placebo. The graph shows two descending lines for placebo and Duloxetine, indicating progressively fewer patients with higher percent pain improvement.*

FDA Label Image

Figure 10 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 11)

A line graph comparing the percentage of patients improved on the vertical axis to the percent improvement in pain from baseline (BOCF) on the horizontal axis for placebo and Duloxetine 60/120 mg once daily. Duloxetine shows a consistently higher percentage of patients improved at all levels of pain improvement compared to placebo.*

FDA Label Image

Image (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 935 1)

Duloxetine 60 mg delayed release capsules label from Bryant Ranch Prepack. The label features two illustrated capsules, each with a dark top half and a lighter bottom half, with several small spheres arranged to form a curved path connecting the capsules.*

FDA Label Image

Image (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 942 1)

Duloxetine 60 mg delayed-release capsules shown in a blister pack with a metallic backing. The capsules are red and opaque, arranged vertically in a row of seven units. No carton or labeler information is visible on the blister pack itself.*

FDA Label Image

Label (Lbl713352567)

Label for Duloxetine Delayed-Release Capsules, USP, 60 mg by Bryant Ranch Prepack. The label shows the NDC 71335-2567-1, indicates 30 capsules per container, and states the product is Rx only. It also notes the product is manufactured by Lupin Limited and includes product storage instructions along with QR codes for more information.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.